Should combination therapy with inhaled corticosteroids and long-acting beta2-agonists be prescribed as initial maintenance treatment for asthma?
Year: 2002
Type: article
Abstract: In March of this year, GlaxoSmithKline (GSK) received approval from Health Canada for a revised product monograph with a new indication for the use of Advair, an aerosol containing both salmeterol, a long-acting β2-agonist, and fluticasone, an inhaled corticosteroid for use in patients with asthma
Source: Europe PMC (PubMed Central)
Institution: Université de Montréal
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2162450621